Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer.

Caio Max S Rocha Lima, Marcos G. Joppert

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer-related death in males and females in the United States. Most patients have advanced disease at diagnosis. Chemotherapy is the treatment of choice for patients with good performance status. Progress in the management ofpatients with advanced disease has been slow, and platinum-based combinations result in a small survival benefit. The topoisomerase I inhibitors are active as single agents and in combination with platinums in non-small-cell lung cancer. Nonplatinum-based doublet combinations are beginning to be explored in an attempt to reduce toxicity and improve efficacy. Data available on some of the nonplatinum doublets that include topoisomerase I inhibitors suggest that these regimens provide efficacy equal to that achieved with platinum-based doublets. This article reviews the topoisomerase I-inhibitor nonplatinum combinations in the management of advanced non-small-cell lung cancer.

Original languageEnglish
Pages (from-to)25-31
Number of pages7
JournalOncology (Williston Park, N.Y.)
Volume16
Issue number9 Suppl 9
StatePublished - Sep 1 2002

Fingerprint

Topoisomerase I Inhibitors
Type I DNA Topoisomerase
Non-Small Cell Lung Carcinoma
Platinum
Lung Neoplasms
Drug Therapy
Survival
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Rocha Lima, C. M. S., & Joppert, M. G. (2002). Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer. Oncology (Williston Park, N.Y.), 16(9 Suppl 9), 25-31.

Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer. / Rocha Lima, Caio Max S; Joppert, Marcos G.

In: Oncology (Williston Park, N.Y.), Vol. 16, No. 9 Suppl 9, 01.09.2002, p. 25-31.

Research output: Contribution to journalArticle

Rocha Lima, CMS & Joppert, MG 2002, 'Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer.', Oncology (Williston Park, N.Y.), vol. 16, no. 9 Suppl 9, pp. 25-31.
Rocha Lima, Caio Max S ; Joppert, Marcos G. / Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer. In: Oncology (Williston Park, N.Y.). 2002 ; Vol. 16, No. 9 Suppl 9. pp. 25-31.
@article{351afd247d524ff0a68a5fe8cafd040a,
title = "Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer.",
abstract = "Lung cancer is the leading cause of cancer-related death in males and females in the United States. Most patients have advanced disease at diagnosis. Chemotherapy is the treatment of choice for patients with good performance status. Progress in the management ofpatients with advanced disease has been slow, and platinum-based combinations result in a small survival benefit. The topoisomerase I inhibitors are active as single agents and in combination with platinums in non-small-cell lung cancer. Nonplatinum-based doublet combinations are beginning to be explored in an attempt to reduce toxicity and improve efficacy. Data available on some of the nonplatinum doublets that include topoisomerase I inhibitors suggest that these regimens provide efficacy equal to that achieved with platinum-based doublets. This article reviews the topoisomerase I-inhibitor nonplatinum combinations in the management of advanced non-small-cell lung cancer.",
author = "{Rocha Lima}, {Caio Max S} and Joppert, {Marcos G.}",
year = "2002",
month = "9",
day = "1",
language = "English",
volume = "16",
pages = "25--31",
journal = "ONCOLOGY (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "9 Suppl 9",

}

TY - JOUR

T1 - Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer.

AU - Rocha Lima, Caio Max S

AU - Joppert, Marcos G.

PY - 2002/9/1

Y1 - 2002/9/1

N2 - Lung cancer is the leading cause of cancer-related death in males and females in the United States. Most patients have advanced disease at diagnosis. Chemotherapy is the treatment of choice for patients with good performance status. Progress in the management ofpatients with advanced disease has been slow, and platinum-based combinations result in a small survival benefit. The topoisomerase I inhibitors are active as single agents and in combination with platinums in non-small-cell lung cancer. Nonplatinum-based doublet combinations are beginning to be explored in an attempt to reduce toxicity and improve efficacy. Data available on some of the nonplatinum doublets that include topoisomerase I inhibitors suggest that these regimens provide efficacy equal to that achieved with platinum-based doublets. This article reviews the topoisomerase I-inhibitor nonplatinum combinations in the management of advanced non-small-cell lung cancer.

AB - Lung cancer is the leading cause of cancer-related death in males and females in the United States. Most patients have advanced disease at diagnosis. Chemotherapy is the treatment of choice for patients with good performance status. Progress in the management ofpatients with advanced disease has been slow, and platinum-based combinations result in a small survival benefit. The topoisomerase I inhibitors are active as single agents and in combination with platinums in non-small-cell lung cancer. Nonplatinum-based doublet combinations are beginning to be explored in an attempt to reduce toxicity and improve efficacy. Data available on some of the nonplatinum doublets that include topoisomerase I inhibitors suggest that these regimens provide efficacy equal to that achieved with platinum-based doublets. This article reviews the topoisomerase I-inhibitor nonplatinum combinations in the management of advanced non-small-cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0036731360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036731360&partnerID=8YFLogxK

M3 - Article

C2 - 12375798

AN - SCOPUS:0036731360

VL - 16

SP - 25

EP - 31

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

SN - 0890-9091

IS - 9 Suppl 9

ER -